About the project

About

Long Waypoint 78 publishes Lantern Axiom, an independent resource on ibogaine, personal development claims, cultural context, research, regulation, and serious safety considerations. Our aim is to help adults separate evidence from hype and to foreground safety before aspiration.

Mission: Lantern Axiom is an independent resource on ibogaine, personal development claims, cultural context, research, regulation, and serious safety considerations. It helps people distinguish evidence, uncertainty, and high-risk promotional narratives.

This page describes the organization, editorial approach, and guiding principles. For the site's topical guides and summaries, refer to the main collection available from the site's entry pages and service descriptions.

Our editorial approach

We gather information from registries, peer-reviewed literature, official regulatory pages, and reputable clinical trial records, then distill what is verifiable while clearly stating uncertainty. For example, when we summarize clinical activity we consult trial registries and trial pages rather than promotional materials; an illustrative registry overview can be found at clinical trial listings in Texas where protocol descriptions are posted.

Our work prioritizes transparent sourcing: what is asserted, where the evidence comes from, and what remains uncertain.

We also cross-check cultural and ethical context against established sources; for general research best-practice guidance see the National Institutes of Health overview at NIH, and for broader context on traditional medicines consult the overview on ethnobotany.

How we vet information

We favor primary sources, registry entries, and peer-reviewed synthesis. Where clinical or legal interpretation is needed we link to authoritative public resources rather than offer legal or medical advice ourselves.

Safety before aspiration

We foreground risk and practical safety information over promotional narratives.

Evidence over hype

Claims are traced to evidence; uncertainty is stated plainly.

Cultural respect

We acknowledge and respect traditional contexts and avoid appropriation in presentation.

What we cover

Long Waypoint 78 organizes content around practical questions an adult reader might have: summaries of research design and outcomes, regulation and safety considerations, conversations about cultural context, and evaluations of promotional claims. We do not provide treatment recommendations or clinical scheduling — instead we point readers to reputable registries and documented clinical resources such as provider directories and clinic information pages when those are appropriate to the question. For example, readers exploring care options sometimes consult clinics listed at treatment clinic directories or region-specific listings like Mexico ibogaine centers, which we reference when describing access pathways without endorsing specific providers.

We also maintain thematic service descriptions about how the resource helps users; those pages include an overview of editorial services and how to request clarifications — see the site's description of available editorial services at our services page.

Who this is for

This resource is aimed at adults seeking careful, non-promotional context on ibogaine and related personal-development claims. It is written for readers who want evidence-first summaries and plain-language explanations of uncertainty. Family members and guides may also find our synthesis useful when preparing to support someone considering risk-laden choices; for guidance intended for close contacts, see our materials under For Families & Guides.

We do not supply clinical assessments, prescriptions, or legal counsel; for formal clinical questions readers are advised to consult licensed professionals and official trial documentation such as registry listings (for an example of trial documentation see ibogaine news and trial summaries).

Sourcing and transparency

Our articles include inline citations and links to primary registries, peer-reviewed literature, and official regulator pages whenever available. We also summarize what evidence exists and where gaps remain. For topic-specific reporting and news aggregation we sometimes reference focused sites that compile clinical and advocacy resources such as ibogaine and depression summaries or intervention-focused initiatives like work on fentanyl-related interventions, always noting the limitations of non-peer-reviewed sources.

When we reference clinical or regulatory status we prefer official registries and pages; readers looking to verify trial status can consult international registries and government health pages such as the U.S. National Library of Medicine's ClinicalTrials.gov for formal trial records (ClinicalTrials.gov).

Independent by design

Long Waypoint 78 is editorially independent. Lantern Axiom is not a clinic, medical provider, or licensed treatment center, and the site's content is not medical or legal advice. Readers should consult licensed professionals for personal medical questions and official regulatory sources for legal guidance.

If you'd like to navigate back to our introductions and topical collections, there are overview entry points on the main site that link to focused guides and thematic pages; try returning to the site's front pages to explore those organized collections at the site's main entry or to review available services at service descriptions.

Additional notes

We avoid promotional language and do not endorse clinics or providers. Where outside organizations or directories are mentioned, they are cited as informational resources only. Readers who want to see aggregated postings and update feeds often consult focused reporting on clinical activity; examples of such reporting sites include ibogaine news today which aggregates developments, and directory sites like best treatment clinic listings that compile provider information.